Clinical trials: Advanced Breast Cancer Stage IV
Neoplasms, Breast
Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC
This is an open-label, non-randomized, multi-center study of lapatinib plus paclitaxel to evaluate safety, tolerability and efficacy in Japanese patients with ErbB2 over expressing advanced or metastatic breast cancer.
- Trial name
- NCT01138046
- Testing
- Lapatinib in combination with weekly paclitaxel
- Where
- 10 sites in Japan
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
To compare the combination of Ribociclib plus goserelin acetate with hormonal therapy versus combination chemotherapy in premenopausal or perimenopausal patients with advanced or metastatic breast cancer
- Trial name
- RIGHT Choice (NCT03839823)
- Testing
- Docetaxel / Capecitabine, Capecitabine / Vinorelbine, Paclitaxel / Gemcitabine
- Where
- 50 sites in Egypt, India and 11 more
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
This study evaluated whether the addition of daily BKM120 to weekly paclitaxel was effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.
- Trial name
- BELLE-4 (NCT01572727)
- Testing
- Paclitaxel, BKM120
- Where
- 112 sites in United States, Australia and 20 more
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Breast Tumors
QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
This is a randomized, double-blind, placebo-controlled, phase 2 study. Subjects will include postmenopausal women with confirmed HR-positive, locally advanced or metastatic breast cancer, who have disease progression during or…
- Conditions
- Breast Cancer, Breast Tumors, Metastatic Cancer
- Trial name
- NCT00626106
- Testing
- AMG 479
- Where
- 60 sites in United States, Australia and 7 more
- Volunteers
- 156 people
- Sponsor
- NantCell, Inc.
Breast Neoplasms, Breast Cancer
BAY43-9006 - Phase II in Advanced Breast Cancer
The purpose of this study is to evaluate the anti-cancer activity and safety of BAY43-9006 (Sorafenib) in patients, who suffer from an advanced breast tumour, which has spread to other organs of body despite treatment that the…
- Trial name
- NCT00101400
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 7 sites in Germany, Italy
- Volunteers
- 54 people
- Sponsor
- Bayer
Breast Cancer
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.
This was a three-arm, randomized, open label, multi-center phase II study investigating the combination of everolimus (10mg daily) with exemestane (25mg daily) versus everolimus (10mg daily) versus capecitabine (1250mg/m2 twice…
- Trial name
- BOLERO-6 (NCT01783444)
- Testing
- Capecitabine, Exemestane, Everolimus
- Where
- 83 sites in United States, Argentina and 16 more
- Volunteers
- 309 people
- Sponsor
- Novartis Pharmaceuticals
Male Breast Cancer, Stage IIIA Breast Cancer
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
This phase I/II trial is studying the side effects and best dose of oblimersen when given together with doxorubicin and docetaxel and to see how well they work in treating women with metastatic or locally advanced breast cancer.
- Conditions
- Male Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT00063934
- Testing
- oblimersen sodium, doxorubicin hydrochloride, docetaxel
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer, Locally Advanced Breast Cancer
Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
To determine how long Gemcitabine and Bevacizumab will stop the cancer from growing in patients with advanced breast cancer.
- Trial name
- NCT00623233
- Testing
- Gemcitabine, Bevacizumab
- Where
- 16 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Post Menopausal Breast Cancer
Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
This international, multi-center, open-label, single-arm study evaluated the safety and tolerability profile of everolimus in post-menopausal women with HR positive, HER2 negative locally advanced or metastatic breast cancer…
- Trial name
- EVEREXES (NCT03176238)
- Testing
- everolimus, exemestane
- Where
- 55 sites in Australia, India and 11 more
- Volunteers
- 235 people
- Sponsor
- Novartis Pharmaceuticals
Estrogen Receptor Positive, HER2 Positive Breast Carcinoma
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
This randomized phase III trial studies fulvestrant and lapatinib to see how well they work compared to fulvestrant and a placebo in treating postmenopausal women with stage III or stage IV breast cancer that is hormone…
- Conditions
- Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Progesterone Receptor Positive
- Trial name
- NCT00390455
- Testing
- Fulvestrant, Laboratory Biomarker Analysis, Lapatinib Ditosylate
- Where
- 368 sites in United States
- Volunteers
- 295 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
There are no treatments specifically approved after recurrence or progression on a non steroidal aromatase inhibitors (NSAI). In light of the need for new treatment options for postmenopausal women after failure of prior NSAI…
- Trial name
- BOLERO-2 (NCT00863655)
- Testing
- Everolimus, Exemestane
- Where
- 200 sites in United States, Australia and 22 more
- Volunteers
- 724 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
STRIDE - STimulating Immune Response In aDvanced brEast Cancer
EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).
- Trial name
- STRIDE (NCT00925548)
- Testing
- Tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
- Where
- 29 sites in United States, Australia and 10 more
- Volunteers
- 16 people
- Sponsor
- EMD Serono
Breast Cancer
Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
The primary objective of this study is to determine if estrogen receptor-targeted therapy with fulvestrant used in combination with Everolimus is an effective and safe therapy for women with hormone receptor positive metastatic…
- Trial name
- BRE-43 (NCT00570921)
- Testing
- Everolimus, Fulvestrant
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mara Chambers
Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage IV
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of bemcentinib (BGB324) in combination with pembrolizumab in participants with previously treated, locally advanced and…
- Trial name
- NCT03184558
- Testing
- Bemcentinib; pembrolizumab
- Where
- 17 sites in United States, Norway and 2 more
- Volunteers
- 29 people
- Sponsor
- BerGenBio ASA
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
This phase II trial tests the how well a precision medicine approach (serial measurements of molecular and architectural response to therapy [SMMART])-adaptive clinical treatment [ACT]) works in treating patients with sarcoma…
- Conditions
- Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma
- Trial name
- NCT06630325
- Testing
- Abemaciclib, Biopsy, Bone Scan
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Neoplasms, Breast Cancer
Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer
This clinical study is designed as an open, single group, multi-center, phase 4 clinical study to assess the safety of eribulin which is approved for the treatment of the patients in Korea with locally advanced or metastatic…
- Trial name
- ESKIMO (NCT01961544)
- Testing
- Eribulin mesylate
- Where
- 14 sites in South Korea
- Volunteers
- 101 people
- Sponsor
- Eisai Korea Inc.
Metastatic Breast Cancer, Neoplasms, Breast
Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
This study is to evaluate the safety and efficacy of lapatinib taken together with capecitabine in Japanese patients. The study will proceed in two phases; the first phase(Part1) will lead to an evaluation of the mainly…
- Trial name
- NCT00477464
- Testing
- Lapatinib, capecitabine
- Where
- 15 sites in Japan
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Metastatic Breast Cancer
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to demonstrate that SYD985 [(vic-)trastuzumab duocarmazine] is superior to physician's choice in prolonging progression free survival.
- Trial name
- TULIP (NCT03262935)
- Testing
- (vic-)trastuzumab duocarmazine, Physician's choice
- Where
- 90 sites in United States, Belgium and 9 more
- Volunteers
- 437 people
- Sponsor
- Byondis B.V.
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
This randomized phase III trial studies exemestane and entinostat to see how well they work compared to exemestane alone in treating patients with hormone receptor-positive breast cancer that has spread to nearby tissue or lymph…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative
- Trial name
- NCT02115282
- Testing
- Biospecimen Collection, Computed Tomography, Entinostat
- Where
- 653 sites in United States, South Africa
- Volunteers
- 608 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
The purpose of this study is to evaluate the efficacy and safety of E7389 in Patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine as prior therapy, and who…
- Trial name
- NCT00246090
- Testing
- E7389
- Where
- 65 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Eisai Inc.